Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.
about
Class II transactivator: mastering the art of major histocompatibility complex expressionAbsence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopesMHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?Enhanced expression of CD74 in gastrointestinal cancers and benign tissuesER stress affects processing of MHC class I-associated peptides.Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells.Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.Get into the groove! Targeting antigens to MHC class II.Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.A retroviral mutagenesis screen identifies Cd74 as a common insertion site in murine B-lymphomas and reveals the existence of a novel IFNgamma-inducible Cd74 isoformHistone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation.Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.Diversity in MHC class II antigen presentation.Introduction of the CIITA gene into tumor cells produces exosomes with enhanced anti-tumor effectsHLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcomeProlonged expression of MHC class I - peptide expression in bone marrow derived retrovirus transfected matured dendritic cells by continuous centrifugation in the presence of IL-4.Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating LymphocytesNovel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-gamma in promyelocytic cells.On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases.Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia.Beyond the classical: influenza virus and the elucidation of alternative MHC class II-restricted antigen processing pathways.Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State.The immunogenicity of L1210 lymphoma clones correlates with their ability to function as antigen-presenting cells.Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells.Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.CIITA mediates interferon-gamma repression of collagen transcription through phosphorylation-dependent interactions with co-repressor molecules.The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells.MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator.pRB is required for interferon-gamma-induction of the MHC class II abeta gene.Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.DNA cancer vaccines: a gene gun approach.Effects of the glucolipid synthase inhibitor, P4, on functional and phenotypic parameters of murine myeloma cells.Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome.
P2860
Q24552298-6BF9BC29-4699-4E24-9944-DC0FA1310939Q24674180-879F7A0D-E7D9-49B5-8249-8EF38628EE5FQ28594418-3C3098C1-A5E6-4E19-B524-9FEA43322012Q30433510-16BEA8F0-1E26-44C9-84C2-FC8C60131CA5Q33409763-5F056104-9E93-4FEC-8A4A-F70FB65FD5A7Q33567728-D8B267AD-A4AD-4A0F-8EDE-144D52C11EF2Q33707475-5A860038-B509-4FA3-A550-8A78FDB40701Q33815384-9C40EC67-BAFF-46E3-B69D-8A6F66E7CDC8Q33860104-B7E1467E-2CB0-499F-841A-2B9A175082C6Q33905329-3C3540A5-0C0C-4FCE-8269-654E9C61A82EQ34012255-E54670AA-B7CC-413D-869E-DF671D464469Q34155000-69344B86-4F72-48B2-BCCE-5C2C584B50B4Q34259644-6142FB9E-2251-4A89-A62F-1E996A048862Q34579769-8D760A64-4E01-4030-B6AA-DF1F407663CDQ35014206-15222AAE-A0AB-407A-9B51-16B753250EFCQ35018702-30A19341-1A2D-4A36-B92B-62A19FC3CFF9Q35646910-B43D9FB7-4BE4-47CF-B0AF-A4B0502D56EFQ35958861-13EDDE6A-6BBD-4890-BD26-65A932683A3DQ36021225-50DEA496-63E1-45F7-88F9-6CAAC2191DCEQ36386903-7E15EB84-ADDD-4574-9EEE-B1579DE2CD0AQ36946744-A67F7555-546F-4093-A003-D7FBD0547332Q37354975-82158CC1-D9D5-4AA6-B306-9E80FAE42842Q37773238-885FD4BB-B473-4B3D-8D30-997CD0880B82Q37958695-458F48E4-553F-479A-ABA4-41E3344F76B2Q38060734-6399C314-6F86-4B26-AC56-26D7CDBCCA72Q38193821-21BC4D5D-F80B-4A5B-B7AC-A07BB49CB680Q39796169-A6D929C6-4300-4F08-8A07-07BA6951EFB0Q39832869-531A495F-DE82-4E69-B08B-A445104524F1Q40011550-D88A4445-4012-495E-B22E-15B3C1125B07Q40054485-DA93859D-7B6C-4AAA-A532-59A5EC90E313Q40088629-8A36F18C-01DA-446D-8566-5F2D524D0111Q40255858-3BE81C2F-D03C-48AA-8902-7A8C09B679BEQ40507425-14E3211A-E4AC-48E7-885B-64383C2A2040Q40621373-86460AB2-6611-4179-9CAD-2ADECBDD0529Q40735560-1D8CD234-6888-4CFA-AD62-875FB010295CQ40928341-A494F67F-29B7-4DFF-B143-9EBD7B820166Q40953949-7A68154C-CFD3-4712-BBCB-B403EA81B221Q41682341-C782266A-B6C0-4498-AECF-A4B368CC8A90Q41788470-BF7A05C5-BD40-4605-8175-B5665919CC15Q41849656-CFDB1C39-B7DF-4F10-8948-0E48CEF293E0
P2860
Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Major histocompatibility compl ...... rs of tumor-specific immunity.
@ast
Major histocompatibility compl ...... rs of tumor-specific immunity.
@en
type
label
Major histocompatibility compl ...... rs of tumor-specific immunity.
@ast
Major histocompatibility compl ...... rs of tumor-specific immunity.
@en
prefLabel
Major histocompatibility compl ...... rs of tumor-specific immunity.
@ast
Major histocompatibility compl ...... rs of tumor-specific immunity.
@en
P2093
P2860
P356
P1476
Major histocompatibility compl ...... rs of tumor-specific immunity.
@en
P2093
B K Martin
S Ostrand-Rosenberg
T D Armstrong
V K Clements
P2860
P304
P356
10.1073/PNAS.94.13.6886
P407
P577
1997-06-01T00:00:00Z